Jim Cramer Spotlights Viking Therapeutics
In a recent segment on CNBC's 'Mad Money Lightning Round', Jim Cramer underscored the potential of Viking Therapeutics, which trades under the ticker VKTX. He expressed strong confidence in the company, saying, “This is a really fine company, and it will do well for multiple years because they have many ships coming in.” This phrase hints at a slew of positive developments expected for the firm, suggesting exciting times ahead for investors.
Analyst Perspectives on Viking Therapeutics
Analyst Hardik Parikh from JPMorgan shares Cramer’s optimism about Viking Therapeutics, as he has initiated coverage with an Overweight rating. He has set a price target of $80 for December 2025, indicating a significant expected upside of 45% based on its latest price of $54.65. This support from a respected analyst lends credibility to Cramer’s bullish viewpoint.
Gentex Corporation: Proceed with Caution
Conversely, Cramer advised caution when it comes to Gentex Corporation, identified by the ticker GNTX. He noted that the company's strong connections to the automotive sector might be a barrier to growth, especially given the current hurdles facing the auto industry. “I don’t see a quick turn. We’re going to need several Fed rate cuts before they turn,” Cramer cautioned, urging investors to stay alert.
Cadre Holdings Displays Potential
On a more encouraging note, Cramer characterized Cadre Holdings, Inc., which trades under the ticker CDRE, as a “good simple story.” Cadre recently reported earnings of 31 cents per share, beating analysts' estimates of 27 cents per share. Additionally, the company’s quarterly sales exceeded expectations, coming in at $144.31 million compared to the predicted $142.05 million, highlighting its strong operational performance.
Celsius Holdings: Areas of Concern
Cramer also raised alarms regarding Celsius Holdings, Inc., trading under the ticker CELH. Mentioning that “Something's the matter with Celsius,” he expressed a desire to uncover the core issues the company faces. Recently, Celsius appointed Hans Melotte to its Board of Directors, a change that could hint at strategic shifts coming down the pipeline.
Stock Price Movements
On a day marked by mixed performance for the stocks discussed, Viking Therapeutics shares rose by 5.8%, closing at $68.16. In comparison, Gentex Corporation shares saw a modest increase of 1.8%, ending at $29.82. Cadre Holdings also experienced gains, with its shares climbing by 2.4% to $37.36. On the flip side, Celsius Holdings faced a dip, as its shares fell by 0.6% to finish at $34.07.
Market Overview: What Lies Ahead?
The insights shared by Jim Cramer reveal ongoing changes within the market and the diverse potential of various stocks. Investors are encouraged to consider these insights closely and keep an eye on further developments related to the stocks of interest.
Frequently Asked Questions
What did Jim Cramer say about Viking Therapeutics?
Cramer emphasized that Viking Therapeutics is a promising company with many opportunities ahead, making it an appealing investment option.
What price target did JPMorgan set for Viking Therapeutics?
JPMorgan analyst Hardik Parikh established a price target of $80 for Viking Therapeutics by December 2025, indicating substantial upside potential.
What is Cramer's view on Gentex Corporation?
Cramer advised caution regarding Gentex, noting that its close ties to the struggling auto sector could impede its recovery.
How did Cadre Holdings perform recently?
Cadre Holdings reported earnings of 31 cents per share, surpassing expectations and demonstrating strong sales performance.
What was Cramer’s assessment of Celsius Holdings?
Cramer pointed out that there are issues with Celsius Holdings and expressed interest in understanding the challenges the company faces more deeply.
